Amarin Corp Plc (AMRN)

[Whalatane]

PSea. My posts regarding Kaiser are relevant to you ( and other investors here ) , in the following way .

There are roughly 10 m patients enrolled in California Kaiser
Lets assume 10% of those are CAD patients on Statin therapy ....1 million patients .

Once the FDA approves the R-IT indication for Vascepa ....are companies like Kaiser going to be willing to take the extra step and make Vascepa available and affordable for every patient they have on Statin therapy ...or only those that are diabetic plus 1 additional risk AND those clinical ASCVD ....which as per poster Mellow's link looks to be secondary prevention.

I think everyone on Statin therapy should be prescribed Vascepa . IMHO it will prove very cost effective to do this and save our healthcare system billions of $ over time .
It would also be good for you as an AMRN investor..

But if Kaiser and other Health providers take a very conservative line ...secondary prevention and diabetics with 1 additional risk factor ONLY to be " on label "...what does that do to your projections of online scripts and how does that affect AMRN's bottom line ?

Regarding medical advice from message boards .
JL recommended that I add high dose EPA to my max dose Statin therapy in mid 2012.
Advice I followed.
The R-IT results ...particularly for those with mixed D like myself ...very low HDL and high TG combination ....has proven the advice ...yes advice from JL on a message board ....some of the best advice I have ever received.

JMO
Kiwi